lilly tirzepatide shortage Mounjaro will remain off shortage list after FDA review

The U.S. Food and Drug Administration (FDA) has recently made significant decisions regarding tirzepatide, a medication marketed by Eli Lilly under the brand names Mounjaro and Zepbound. Resolution of Tirzepatide Shortage: On

24.21

★★★★☆4.8 (126)

FDA has announced that the shortage of #tirzepatide, the ingredient in Lilly's Mounjaro and Zepbound, has been resolved. Compounding #pharmacies are required to cease production of compounded versions of tirzepatide within the

21.20

★★★★★4.9 (98)

Lilly's Tirzepatide Could Land Again on FDA Drug Shortage List, Opens Door for Compounders

27.30

★★★★★5.0 (157)

Heard about the Eli Lilly lawsuit? 👀 They're suing two pharmacies for selling compounded versions of tirzepatide (aka Mounjaro/Zepbound). Not FDA-approved. No current shortage. Big red flag 🚩 Moral of the story?

21.82

★★★★★4.7 (84)

Shortages improve for Lilly's GLP-1 weight loss drugs, bumping sales forecast by $3bn

26.52

★★★★★4.9 (203)

The FDA Can't Decide Whether Zepbound Is in Shortage. Hims & Hers Stock Jumps

29.16

★★★★★5.0 (176)

FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next

25.34

★★★★★4.8 (132)